Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Mineralys Therapeutics, Inc. roa for the quarter ending 2026-06-30 was -52.34%, a change of 4.48% year-over-year.
Mineralys Therapeutics, Inc. roa for the quarter ending 2026-03-31 was -23.25%, a change of 29.86% year-over-year.
Mineralys Therapeutics, Inc. roa for the quarter ending 2025-12-31 was -23.37%, a change of 62.99% year-over-year.
Mineralys Therapeutics, Inc. roa for the quarter ending 2025-09-30 was -28.56%, a change of 28.57% year-over-year.
Mineralys Therapeutics, Inc. roa for fiscal 2025 was -23.37%, a change of 62.99% from fiscal 2024.
Mineralys Therapeutics, Inc. roa for fiscal 2024 was -86.36%, a change of -57.78% from fiscal 2023.
Mineralys Therapeutics, Inc. roa for fiscal 2023 was -28.57%, a change of -2.53% from fiscal 2022.
Mineralys Therapeutics, Inc. roa for fiscal 2022 was -26.04%.